<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TNKASE- tenecteplase 
			 </strong><br>Genentech, Inc.<br></p></div>
<h1>TNKase<span class="Sup">®</span><br>(Tenecteplase)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">TNKase<span class="Sup">®</span> (Tenecteplase) is a tissue
							<span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> activator (tPA) produced by recombinant DNA technology using
							an established mammalian cell line (Chinese Hamster Ovary cells).
							Tenecteplase is a 527 amino acid glycoprotein developed by introducing
							the following modifications to the complementary DNA (cDNA) for natural
							human tPA: a substitution of threonine 103 with asparagine, and a
							substitution of asparagine 117 with glutamine, both within the kringle 1
							domain, and a tetra-alanine substitution at amino acids
							296–299 in the protease domain. Cell culture is carried out in
							nutrient medium containing the antibiotic gentamicin (65 mg/L). However,
							the presence of the antibiotic is not detectable in the final product
							(limit of detection is 0.67 µg/vial). TNKase is a sterile,
							white to off-white, lyophilized powder for single intravenous (IV) bolus
							administration after reconstitution with Sterile Water for Injection
							(SWFI), USP. Each vial of TNKase nominally contains 52.5 mg
							Tenecteplase, 0.55 g L-arginine, 0.17 g phosphoric acid, and 4.3 mg
							polysorbate 20, which includes a 5% overfill. Each vial will
							deliver 50 mg of Tenecteplase.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2>General</h2>
<p class="First">Tenecteplase is a modified form of human tissue
									<span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> activator (tPA) that binds to fibrin and converts
									<span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> to plasmin. In the presence of fibrin, <span class="Italics">in vitro</span> studies demonstrate
									that Tenecteplase conversion of <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> to plasmin is
									increased relative to its conversion in the absence of fibrin.
									This fibrin specificity decreases systemic activation of
									<span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> and the resulting degradation of circulating
									fibrinogen as compared to a molecule lacking this property.
									Following administration of 30, 40, or 50 mg of TNKase, there
									are decreases in circulating fibrinogen
									(4%–15%) and <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span>
									(11%–24%). The clinical significance
									of fibrin-specificity on safety (e.g., <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>) or efficacy has
									not been established. Biological potency is determined by an <span class="Italics">in vitro</span> clot lysis
									assay and is expressed in Tenecteplase-specific units. The
									specific activity of Tenecteplase has been defined as 200
									units/mg. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> (AMI),
									TNKase administered as a single bolus exhibits a biphasic
									disposition from the plasma. Tenecteplase was cleared from the
									plasma with an initial half-life of 20 to 24 minutes. The
									terminal phase half-life of Tenecteplase was 90 to 130 minutes.
									In 99 of 104 patients treated with Tenecteplase, mean plasma
									clearance ranged from 99 to 119 mL/min.</p>
<p>The initial volume of distribution is weight related and
									approximates plasma volume. Liver metabolism is the major
									clearance mechanism for Tenecteplase.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Clinical_Studies"></a><a name="section-3"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">ASSENT-2 was an international, randomized, double-blind trial
							that compared 30-day mortality rates in 16,949 patients
							assigned to receive an IV bolus dose of TNKase or an accelerated
							infusion of Activase<span class="Sup">®</span> (Alteplase).<span class="Sup"><a href="#References">1</a></span> Eligibility criteria included onset of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> within
							6 hours of randomization and ST-segment elevation or left
							<span class="product-label-link" type="condition" conceptid="313791" conceptname="Bundle branch block">bundle branch block</span> on electrocardiogram (ECG). Patients were to be
							excluded from the trial if they received GP IIb/IIIa inhibitors within
							the previous 12 hours. TNKase was dosed using actual or
							estimated weight in a weight-tiered fashion as described in <a href="#DosageAndAdministration">DOSAGE AND
							ADMINISTRATION</a>. All patients were to receive
							150–325 mg of aspirin administered as soon as
							possible, followed by 150–325 mg daily. Intravenous
							heparin was to be administered as soon as possible: for patients
							weighing ≤67 kg, heparin was administered as a
							4000 unit IV bolus followed by infusion at 800 U/hr;
							for patients weighing &gt;67 kg, heparin was administered
							as a 5000 unit IV bolus followed by infusion at 1000 U/hr.
							Heparin was continued for 48 to 72 hours with infusion adjusted
							to maintain aPTT at 50–75 seconds. The use of GP IIb/IIIa
							inhibitors was discouraged for the first 24 hours following
							randomization. The results of the primary endpoint (30-day mortality
							rates with non-parametric adjustment for the covariates of age, Killip
							class, heart rate, systolic blood pressure and infarct location) along
							with selected other 30-day endpoints are shown in Table 1.</p>
<table width="65%">
<caption><span>Table 1 ASSENT-2 Mortality, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>, and Combined Outcome of
								<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> Measured at Thirty Days</span></caption>
<col align="left" width="25%">
<col align="center" width="12.5%">
<col align="center" width="12.5%">
<col align="center" width="15%">
<thead><tr class="First Last">
<th class="Lrule" align="left" valign="bottom">30-Day Events</th>
<th align="center" valign="bottom">TNKase<br>(n = 8461)</th>
<th align="center" valign="bottom">Accelerated Activase<br>(n = 8488)</th>
<th class="Botrule Rrule" align="center">Relative Risk
										TNKase/Activase<br>(95% CI)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule" align="left">Mortality</td>
<td align="center">6.2%</td>
<td align="center">6.2%</td>
<td class="Rrule" align="center">1.00<br>(0.89, 1.12)</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">Intracranial Hemorrhage</span> (ICH)</td>
<td align="center">0.9%</td>
<td align="center">0.9%</td>
<td class="Rrule" align="center">0.99 <br>(0.73, 1.35)</td>
</tr>
<tr>
<td class="Lrule" align="left">Any <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></td>
<td align="center">1.8%</td>
<td align="center">1.7%</td>
<td class="Rrule" align="center">1.07 <br>(0.86, 1.35)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> or Nonfatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></td>
<td align="center">7.1%</td>
<td align="center">7.0%</td>
<td class="Rrule" align="center">1.01 <br> (0.91, 1.13)</td>
</tr>
</tbody>
</table>
<p>Rates of mortality and the combined endpoint of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>
							among pre-specified subgroups, including age, gender, time to treatment,
							infarct location, and history of previous <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>,
							demonstrate consistent relative risks across these subgroups. There was
							insufficient enrollment of non-Caucasian patients to draw any
							conclusions regarding relative efficacy in racial subsets.</p>
<p>Rates of in-hospital procedures, including percutaneous
							transluminal coronary angioplasty (PTCA), stent placement, intra-aortic
							balloon pump (IABP) use, and coronary artery bypass graft (CABG)
							surgery, were similar between the TNKase and Activase<span class="Sup">®</span>(Alteplase) groups.</p>
<p>TIMI 10B was an open-label, controlled, randomized, dose-ranging,
							angiography study which utilized a blinded core laboratory for review of
							coronary arteriograms.<span class="Sup"><a href="#References">2</a></span> Patients (n = 837) presenting within 12 hours of symptom
							onset were treated with fixed doses of 30, 40, or 50 mg of TNKase or the
							accelerated infusion of Activase and underwent coronary arteriography at
							90 minutes. The results showed that the 40 mg and 50 mg doses were
							similar to accelerated infusion of Activase in restoring patency. TIMI
							Grade 3 flow and TIMI Grade 2/3 flow at 90 minutes are shown in Table 2.
							The exact relationship between coronary artery patency and clinical
							activity has not been established.</p>
<table width="80%">
<caption><span>Table 2 TIMI 10B Patency Rates TIMI Grade Flow at 90 Minutes</span></caption>
<col align="left" width="16%">
<col align="center" width="16%">
<col align="center" width="16%">
<col align="center" width="16%">
<col align="center" width="16%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th align="center">Activase ≤100 mg<br>(n=311)</th>
<th align="center">TNKase 30 mg<br>(n=302)</th>
<th align="center">TNKase 40 mg<br>(n=148)</th>
<th class="Rrule" align="center">TNKase 50 mg<br>(n=76)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule" align="left">TIMI Grade 3 Flow</td>
<td align="center">63%</td>
<td align="center">54%</td>
<td align="center">63%</td>
<td class="Rrule" align="center">66%</td>
</tr>
<tr>
<td class="Lrule" align="left">TIMI Grade 2/3 Flow</td>
<td align="center">82%</td>
<td align="center">77%</td>
<td align="center">79%</td>
<td class="Rrule" align="center">88%</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">95% CI<br>(TIMI 2/3 Flow)</td>
<td align="center">(77%,86%)</td>
<td align="center">(72%,81%)</td>
<td align="center">(72%,85%)</td>
<td class="Rrule" align="center">(79%,94%)</td>
</tr>
</tbody>
</table>
<p>The angiographic results from TIMI 10B and the safety data from
							ASSENT-1, an additional uncontrolled safety study of 3,235
							TNKase-treated patients, provided the framework to develop a
							weight-tiered TNKase dose regimen.<span class="Sup"><a href="#References">3</a></span> Exploratory analyses suggested that a weight-adjusted dose of
							0.5 mg/kg to 0.6 mg/kg of TNKase resulted in a better patency to
							<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> relationship than fixed doses of TNKase across a broad range of
							patient weights.</p>
<p>The Assessment of the Safety and Efficacy of a New Treatment
							Strategy with Percutaneous Coronary Intervention (ASSENT 4 PCI) was a
							Phase IIIb/IV study designed to assess the safety and effectiveness
							of a strategy of administering full dose TNKase with a single bolus of
							4000 U of unfractionated heparin in patients with ST segment
							elevation AMI, in whom primary percutaneous coronary intervention (PCI)
							was planned, but in whom a delay of 1–3 hours was anticipated before
							PCI. The trial was prematurely terminated with 1667 randomized
							patients (75 of whom were treated in the United States) due to a
							numerically higher mortality in the patients receiving TNKase prior to
							primary PCI versus PCI without TNKase (median time from randomization to
							balloon of 115 minutes). The incidence of the 90‑day
							primary endpoint, a composite of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span> or
							<span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (CHF) within 90 days, was 18.6% in
							patients treated with TNKase plus PCI versus 13.4% in those treated with
							PCI alone (p=0.0055; OR 1.39 (95% C.I. 1.11–1.74)). </p>
<p>There were trends toward worse outcomes in the individual
							components of the primary endpoint between TNKase plus PCI versus PCI
							alone (mortality 6.7% vs. 5.0%, respectively; <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span> 6.1% vs.
							4.8%, respectively; and CHF 12.1% vs. 9.4%, respectively). In addition,
							there were trends towards worse outcomes in recurrent MI (6.1% vs. 3.5%,
							respectively; p=0.03) and repeat target vessel revascularization (6.6%
							vs. 3.6%, respectively; p=0.005) in patients receiving TNKase plus PCI
							versus PCI alone.</p>
<p>There was no difference in in‑hospital major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>
							between the two groups (5.6% vs. 4.4% for TNKase plus PCI vs. PCI alone,
							respectively). For patients treated with TNKase plus PCI, in‑hospital
							rates of <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> and total <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> were similar to those
							observed in previous trials (0.97% and 1.8%, respectively); however,
							none of the patients treated with PCI alone experienced a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>
							(ischemic, hemorrhagic or other).</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">TNKase<span class="Sup">®</span> (Tenecteplase) is indicated for use
							in the reduction of mortality associated with acute myocardial
							<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> (AMI). Treatment should be initiated as soon as possible
							after the onset of AMI symptoms (see <a href="#Clinical_Studies">CLINICAL STUDIES</a>).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="Bold">TNKase therapy in patients with acute
								<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> is contraindicated in the following situations
								because of an increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (see <a href="#Warnings">WARNINGS</a>):</span></p>
<ul>
<li><span class="Bold">Active internal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></span></li>
<li><span class="Bold">History of cerebrovascular
								<span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span></span></li>
<li><span class="Bold">Intracranial or intraspinal surgery or
									<span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> within 2 months</span></li>
<li><span class="Bold">Intracranial neoplasm, arteriovenous
									malformation, or <span class="product-label-link" type="condition" conceptid="4311963" conceptname="Aneurysm">aneurysm</span></span></li>
<li><span class="Bold">Known <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> diathesis</span></li>
<li><span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span></span></li>
</ul>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">The most common complication encountered during TNKase
									therapy is <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. The type of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with
									thrombolytic therapy can be divided into two broad categories:</p>
<ul>
<li>Internal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, involving intracranial and
										retroperitoneal sites, or the gastrointestinal,
										genitourinary, or respiratory tracts.</li>
<li>Superficial or surface <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, observed mainly at
										vascular puncture and access sites (e.g., venous cutdowns,
										arterial punctures) or sites of recent surgical
										intervention.</li>
</ul>
<p>Should serious <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (not controlled by local
									pressure) occur, any concomitant heparin or antiplatelet agents
									should be discontinued immediately.</p>
<p>In clinical studies of TNKase, patients were treated with
									both aspirin and heparin. Heparin may contribute to the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>
									risks associated with TNKase. The safety of the use of TNKase
									with other antiplatelet agents has not been adequately studied
									(see <a href="#Drug_Interactions">PRECAUTIONS: Drug
										Interactions</a>). Intramuscular injections and
									nonessential handling of the patient should be avoided for the
									first few hours following treatment with TNKase. Venipunctures
									should be performed and monitored carefully.</p>
<p>Should an arterial puncture be necessary during the first
									few hours following TNKase therapy, it is preferable to use an
									upper extremity vessel that is accessible to manual compression.
									Pressure should be applied for at least 30 minutes, a pressure
									dressing applied, and the puncture site checked frequently for
									evidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p>Each patient being considered for therapy with TNKase
									should be carefully evaluated and anticipated benefits weighed
									against potential risks associated with therapy. In the
									following conditions, the risk of TNKase therapy may be
									increased and should be weighed against the anticipated
									benefits: </p>
<ul>
<li>Recent major surgery, e.g., coronary artery bypass graft,
										obstetrical delivery, organ biopsy, previous puncture of
										noncompressible vessels</li>
<li>Cerebrovascular disease</li>
<li>Recent gastrointestinal or genitourinary <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></li>
<li>Recent <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span></li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>: systolic BP ≥180 mm Hg and/or
										diastolic BP ≥110 mm Hg</li>
<li>High likelihood of left heart thrombus, e.g., mitral
										stenosis with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span></li>
<li><span class="product-label-link" type="condition" conceptid="320116" conceptname="Acute pericarditis">Acute pericarditis</span></li>
<li><span class="product-label-link" type="condition" conceptid="4249899" conceptname="Subacute bacterial endocarditis">Subacute bacterial endocarditis</span></li>
<li>Hemostatic defects, including those secondary to severe
										hepatic or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span></li>
<li>Severe hepatic dysfunction</li>
<li>Pregnancy</li>
<li>Diabetic hemorrhagic <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span> or other hemorrhagic
										ophthalmic conditions</li>
<li>Septic <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> or occluded AV cannula at
										seriously infected site</li>
<li>Advanced age (see <a href="#Geriatric_Use">PRECAUTIONS: Geriatric Use</a>) </li>
<li>Patients currently receiving oral anticoagulants, e.g.,
										warfarin sodium</li>
<li>Recent administration of GP IIb/IIIa inhibitors</li>
<li>Any other condition in which <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> constitutes a
										significant hazard or would be particularly difficult to
										manage because of its location</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4057039" conceptname="Fat embolism">Cholesterol Embolization</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> has been reported rarely in patients
									treated with all types of thrombolytic agents; the true
									incidence is unknown. This serious condition, which can be
									lethal, is also associated with invasive vascular procedures
									(e.g., cardiac catheterization, angiography, vascular surgery)
									and/or anticoagulant therapy. Clinical features of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>
									<span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> may include <span class="product-label-link" type="condition" conceptid="4081096" conceptname="Livedo reticularis">livedo reticularis</span>, "purple
									toe" syndrome, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, gangrenous digits,
									<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, cerebral
									<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>, <span class="product-label-link" type="condition" conceptid="4269209" conceptname="Acute infarction of spinal cord">spinal cord infarction</span>, <span class="product-label-link" type="condition" conceptid="4334245" conceptname="Retinal artery occlusion">retinal artery occlusion</span>,
									bowel <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>, and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span></h2>
<p class="First">Coronary <span class="product-label-link" type="condition" conceptid="4196955" conceptname="Thrombolysis">thrombolysis</span> may result in <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>
									associated with reperfusion. These <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> (such as sinus									<span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4247537" conceptname="Accelerated idioventricular rhythm">accelerated idioventricular rhythm</span>, ventricular
									premature depolarizations, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>) are not
									different from those often seen in the ordinary course of acute
									<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and may be managed with standard
									anti‑arrhythmic measures. It is recommended that anti‑arrhythmic
									therapy for <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and/or ventricular <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> be
									available when TNKase is administered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.4"></a><p></p>
<h2>Use with Percutaneous Coronary Intervention (PCI)</h2>
<p class="First">In patients with large <span class="product-label-link" type="condition" conceptid="4295129" conceptname="ST segment elevation">ST segment elevation</span> myocardial
									<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>, physicians should choose either <span class="product-label-link" type="condition" conceptid="4196955" conceptname="Thrombolysis">thrombolysis</span> or PCI
									as the primary treatment strategy for reperfusion. Rescue PCI or
									subsequent elective PCI may be performed after administration of
									thrombolytic therapies if medically appropriate; however, the
									optimal use of adjunctive antithrombotic and antiplatelet
									therapies in this setting is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Standard management of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> should be
									implemented concomitantly with TNKase treatment. Arterial and
									venous punctures should be minimized. Noncompressible arterial
									puncture must be avoided and internal jugular and subclavian
									venous punctures should be avoided to minimize <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from the
									noncompressible sites. In the event of serious <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, heparin
									and antiplatelet agents should be discontinued immediately.
									Heparin effects can be reversed by protamine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>Readministration</h2>
<p class="First">Readministration of <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> activators, including
									TNKase, to patients who have received prior <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span>
									activator therapy has not been systematically studied. Three of
									487 patients tested for antibody formation to TNKase had a
									positive antibody titer at 30 days. The data reflect the
									percentage of patients whose test results were considered
									positive for antibodies to TNKase in a radioimmunoprecipitation
									assay, and are highly dependent on the sensitivity and
									specificity of the assay. Additionally, the observed incidence
									of antibody positivity in an assay may be influenced by several
									factors including sample handling, concomitant medications, and
									underlying disease. For these reasons, comparison of the
									incidence of antibodies to TNKase with the incidence of
									antibodies to other products may be misleading. Although
									sustained antibody formation in patients receiving one dose of
									TNKase has not been documented, readministration should be
									undertaken with caution. If an <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> occurs,
									appropriate therapy should be administered. </p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Drug_Interactions"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Formal interaction studies of TNKase with other drugs
									have not been performed. Patients studied in clinical trials of
									TNKase were routinely treated with heparin and aspirin.
									Anticoagulants (such as heparin and vitamin K antagonists) and
									drugs that alter platelet function (such as acetylsalicylic
									acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the
									risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> if administered prior to, during, or after
									TNKase therapy.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-7.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions </h2>
<p class="First">During TNKase therapy, results of coagulation tests
									and/or measures of fibrinolytic activity may be unreliable
									unless specific precautions are taken to prevent <span class="Italics">in vitro</span> artifacts.
									Tenecteplase is an enzyme that, when present in blood in
									pharmacologic concentrations, remains active under <span class="Italics">in vitro</span> conditions. This can
									lead to degradation of fibrinogen in blood samples removed for
									analysis.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Studies in animals have not been performed to evaluate
									the carcinogenic potential, mutagenicity, or the effect on
									fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.6"></a><p></p>
<h2>Pregnancy (Category C)</h2>
<p class="First">TNKase has been shown to elicit maternal and embryo
									toxicity in rabbits given multiple IV administrations. In
									rabbits administered 0.5, 1.5, and 5.0 mg/kg/day, vaginal
									<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> resulted in maternal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>. Subsequent embryonic
									<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were secondary to maternal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> and no fetal
									anomalies were observed. TNKase does not elicit maternal and
									embryo toxicity in rabbits following a single IV administration.
									Thus, in developmental toxicity studies conducted in rabbits,
									the no observable effect level (NOEL) of a single IV
									administration of TNKase on maternal or developmental toxicity
									was 5 mg/kg (approximately 8–10 times the human dose).
									There are no adequate and well‑controlled studies in pregnant
									women. TNKase should be given to pregnant women only if the
									potential benefits justify the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known if TNKase is excreted in human milk.
									Because many drugs are excreted in human milk, caution should be
									exercised when TNKase is administered to a nursing
								woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety and effectiveness of TNKase in pediatric
									patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Geriatric_Use"></a><a name="section-7.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Of the patients in ASSENT-2 who received TNKase, 4,958
									(59%) were under the age of 65; 2,256 (27%) were
									between the ages of 65 and 74; and 1,244 (15%) were 75
									and over. The 30-day mortality rates by age were 2.5% in
									patients under the age of 65, 8.5% in patients between
									the ages of 65 and 74, and 16.2% in patients age 75 and
									over. The ICH rates were 0.4% in patients under the age
									of 65, 1.6% in patients between the ages of 65 and 74,
									and 1.7% in patients age 75 and over. The rates of any
									<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> were 1.0% in patients under the age of 65,
									2.9% in patients between the ages of 65 and 74, and
									3.0% in patients age 75 and over. Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> rates,
									defined as <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> requiring blood transfusion or leading to
									hemodynamic compromise, were 3.1% in patients under the
									age of 65, 6.4% in patients between the ages of 65 and
									74, and 7.7% in patients age 75 and over. In elderly
									patients, the benefits of TNKase on mortality should be
									carefully weighed against the risk of increased adverse events,
									including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">The most frequent adverse reaction associated with TNKase
									is <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (see <a href="#Warnings">WARNINGS</a>).</p>
<p>Should serious <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occur, concomitant heparin and
									antiplatelet therapy should be discontinued. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> or permanent
									<span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> can occur in patients who experience <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or
									serious <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes.</p>
<p>For TNKase-treated patients in ASSENT-2, the incidence of
									<span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> was 0.9% and any <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was
									1.8%. The incidence of all <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, including
									intracranial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, increases with increasing age (see <a href="#Geriatric_Use">PRECAUTIONS: Geriatric
									Use</a>). </p>
<p>In the ASSENT-2 study, the following <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events were
									reported (see <a href="#Table_3">Table 3</a>). </p>
<a name="Table_3"></a><table width="80%">
<caption><span>Table 3 ASSENT-2 Non-ICH <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Events</span></caption>
<col align="left" width="18%">
<col align="center" width="20%">
<col align="center" width="20%">
<col align="center" width="22%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th align="center">TNKase<br>(n = 8461)</th>
<th align="center">Accelerated Activase<br>(n = 8488)</th>
<th class="Rrule" align="center">Relative Risk for TNKase/Activase
												(95% CI)</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is defined as
												<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> requiring blood transfusion or leading
												to hemodynamic compromise.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left">Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td align="center">4.7%</td>
<td align="center">5.9%</td>
<td class="Rrule" align="center">0.78 (0.69, 0.89)</td>
</tr>
<tr>
<td class="Lrule" align="left">Minor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></td>
<td align="center">21.8%</td>
<td align="center">23.0%</td>
<td class="Rrule" align="center">0.94 (0.89, 1.00)</td>
</tr>
<tr>
<td class="Lrule" align="left">Units of transfused blood</td>
<td align="center"></td>
<td align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">   Any</td>
<td align="center">4.3%</td>
<td align="center">5.5%</td>
<td class="Rrule" align="center">0.77 (0.67, 0.89)</td>
</tr>
<tr>
<td class="Lrule" align="left">   1–2</td>
<td align="center">2.6%</td>
<td align="center">3.2%</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">   &gt;2</td>
<td align="center">1.7%</td>
<td align="center">2.2%</td>
<td class="Rrule" align="center"></td>
</tr>
</tbody>
</table>
<p>Non-intracranial major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and the need for blood
									transfusions were lower in patients treated with TNKase.</p>
<p>Types of major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> reported in 1% or more of
									the patients were <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> (1.7%) and gastrointestinal
									tract (1%). Types of major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> reported in less
									than 1% of the patients were urinary tract, puncture
									site (including cardiac catheterization site), retroperitoneal,
									respiratory tract, and unspecified. Types of minor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>
									reported in 1% or more of the patients were <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>
									(12.3%), urinary tract (3.7%), puncture site
									(including cardiac catheterization site) (3.6%),
									pharyngeal (3.1%), gastrointestinal tract
									(1.9%), <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span> (1.5%), and unspecified
									(1.3%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First">Allergic-type reactions (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>,
									<span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>) have rarely (&lt;
									1%) been reported in patients treated with TNKase.
									<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> was reported in &lt; 0.1% of patients
									treated with TNKase; however, causality was not established.
									When such reactions occur, they usually respond to conventional
									therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2>Other Adverse Reactions</h2>
<p class="First">The following adverse reactions have been reported among
									patients receiving TNKase in clinical trials. These reactions
									are frequent sequelae of the underlying disease, and the effect
									of TNKase on the incidence of these events is unknown.</p>
<p>These events include <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>,
									<span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, cardiac
									arrest, recurrent <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial reinfarction</span>,
									<span class="product-label-link" type="condition" conceptid="4107225" conceptname="Rupture of heart">myocardial rupture</span>, <span class="product-label-link" type="condition" conceptid="318450" conceptname="Cardiac tamponade">cardiac tamponade</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, pericardial
									<span class="product-label-link" type="condition" conceptid="4215818" conceptname="Effusion">effusion</span>, <span class="product-label-link" type="condition" conceptid="443962" conceptname="Mitral valve regurgitation">mitral regurgitation</span>, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span>, and
									<span class="product-label-link" type="condition" conceptid="4122762" conceptname="Electromechanical dissociation">electromechanical dissociation</span>. These events can be
									life-threatening and may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>,							<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> have also been reported.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DosageAndAdministration"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Dosage</h2>
<p class="First">TNKase<span class="Sup">®</span> (Tenecteplase) is for
									intravenous administration only. The recommended total dose
									should not exceed 50 mg and is based upon patient weight. </p>
<p>A single bolus dose should be administered over 5 seconds
									based on patient weight. Treatment should be initiated as soon
									as possible after the onset of AMI symptoms (see <a href="#Clinical_Studies">CLINICAL STUDIES</a>).</p>
<a name="Dosetable"></a><table width="45%">
<caption><span>Dose Information Table</span></caption>
<col align="center" valign="bottom" width="15%">
<col align="center" valign="bottom" width="15%">
<col align="center" valign="bottom" width="15%">
<thead><tr class="First Last">
<th class="Lrule" align="center" valign="bottom">Patient
												Weight<br>(kg)</th>
<th align="center" valign="bottom">TNKase<br>(mg)</th>
<th class="Rrule" align="center" valign="bottom">Volume
												TNKase<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
												to be administered (mL)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>From one vial of
												TNKase reconstituted with 10 mL SWFI.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="center">&lt;60</td>
<td align="center">30</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr>
<td class="Lrule" align="center"> ≥60 to &lt;70</td>
<td align="center">35</td>
<td class="Rrule" align="center">7</td>
</tr>
<tr>
<td class="Lrule" align="center"> ≥70 to &lt;80</td>
<td align="center">40</td>
<td class="Rrule" align="center">8</td>
</tr>
<tr>
<td class="Lrule" align="center"> ≥80 to &lt;90</td>
<td align="center">45</td>
<td class="Rrule" align="center">9</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center"> ≥90</td>
<td align="center">50</td>
<td class="Rrule" align="center">10</td>
</tr>
</tbody>
</table>
<p>The safety and efficacy of TNKase have only been
									investigated with concomitant administration of heparin and
									aspirin as described in <a href="#Clinical_Studies">CLINICAL STUDIES</a>.</p>
<p class="Bold">THE <img alt="B-D" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66a1e273-ab59-4e7a-a223-a96b86501f51&amp;name=1a9e312c-f0b0-4139-b526-b904b80883a4-01.jpg"><span class="Sup">® </span>10 mL SYRINGE WITH
									TWINPAK<span class="Sup">™</span> DUAL CANNULA DEVICE</p>
<p><a name="figure"></a><img alt="DUAL CANNULA DEVICE" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66a1e273-ab59-4e7a-a223-a96b86501f51&amp;name=1a9e312c-f0b0-4139-b526-b904b80883a4-02.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Reconstitution</h2>
<p class="First"><span class="Underline">NOTE</span>: Read all
									instructions completely before beginning reconstitution and
									administration.</p>
<ol>
<li>
<p class="First">Remove the shield assembly from the supplied
												B-D<span class="Sup">®</span> 10 mL syringe with
												TwinPak<span class="Sup">™</span> Dual Cannula Device
												(see <a href="#figure">figure</a>) and aseptically withdraw 10 mL of
											Sterile Water for Injection (SWFI), USP, from the
											supplied diluent vial using the red hub cannula syringe
											filling device. Do not use Bacteriostatic Water for
											Injection, USP.</p>
<p>Note: Do not discard the shield
										assembly.</p>
</li>
<li>Inject the entire contents of the syringe (10 mL) into the
										TNKase vial directing the diluent stream into the powder.
										Slight foaming upon reconstitution is not unusual; any large
										bubbles will dissipate if the product is allowed to stand
										undisturbed for several minutes.</li>
<li>Gently swirl until contents are completely dissolved. DO
										NOT SHAKE. The reconstituted preparation results in a
										colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow transparent solution containing
										TNKase at 5 mg/mL at a pH of approximately 7.3. The
										<span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of this solution is approximately 290 mOsm/kg.</li>
<li>Determine the appropriate dose of TNKase (see <a href="#Dosetable">Dose Information Table</a>) and
										withdraw this volume (in milliliters) from the reconstituted
										vial with the syringe. <span class="Bold">Any unused
											solution should be discarded.</span>
</li>
<li>Once the appropriate dose of TNKase is drawn into the
										syringe, stand the shield vertically on a flat surface (with
										green side down) and passively recap the red hub cannula.</li>
<li>Remove the entire shield assembly, including the red hub
										cannula, by twisting counterclockwise. Note: The shield
										assembly also contains the clear-ended blunt plastic
										cannula; retain for split septum IV access. </li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.3"></a><p></p>
<h2>Administration</h2>
<dl>
<dt>1.</dt>
<dd>The product should be visually inspected prior to administration for particulate matter and discoloration. TNKase may be administered as reconstituted at 5 mg/mL.</dd>
<dt>2.</dt>
<dd>Precipitation may occur when TNKase is administered in an IV line containing dextrose. Dextrose-containing lines should be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> with a saline-containing solution prior to and following single bolus administration of TNKase.</dd>
<dt>3.</dt>
<dd>Reconstituted TNKase should be administered as a single IV bolus over 5 seconds. </dd>
<dt>4.</dt>
<dd>Because TNKase contains no antibacterial preservatives, it should be reconstituted immediately before use. If the reconstituted TNKase is not used immediately, refrigerate the TNKase vial at 2–8°C (36–46°F) and use within 8 hours. </dd>
<dt>5.</dt>
<dd>Although the supplied syringe is compatible with a conventional needle, this syringe is designed to be used with needleless IV systems. From the information below, follow the instructions applicable to the IV system in use.</dd>
</dl>
<table width="80%">
<col align="left" width="30%">
<col align="left" width="50%">
<tbody class="Headless">
<tr class="First">
<td align="left" valign="top"><span class="Bold">Split septum IV system:</span></td>
<td align="left"><ul>
<li>Remove the green cap.</li>
<li>Attach the clear-ended blunt plastic cannula to the syringe.</li>
<li>Remove the shield and use the blunt plastic cannula to access the split septum injection port.</li>
<li>Because the blunt plastic cannula has two side ports, air or fluid expelled through the cannula will exit in two sideways directions; direct away from face or mucous membranes.</li>
</ul></td>
</tr>
<tr>
<td align="left"><span class="Bold">Luer-Lok<span class="Sup">®</span> system:</span></td>
<td align="left">Connect syringe directly to IV port.</td>
</tr>
<tr class="Last">
<td align="left"><span class="Bold">Conventional needle (not supplied in this kit):</span></td>
<td align="left">Attach a large bore needle, e.g., 18 gauge, to the syringe's universal Luer‑Lok<span class="Sup">®</span>.</td>
</tr>
</tbody>
</table>
<dl>
<dt>6.</dt>
<dd>Dispose of the syringe, cannula and shield per established procedures.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">TNKase<span class="Sup">®</span> (Tenecteplase) is supplied as a sterile, lyophilized powder in a 50 mg vial under partial vacuum. Each 50 mg vial of TNKase is packaged with one 10 mL vial of Sterile Water for Injection, USP for reconstitution, the B-D<span class="Sup">®</span> 10 mL syringe with TwinPak<span class="Sup">™</span> Dual Cannula Device, and three alcohol prep pads. NDC 50242-120-01.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Stability and Storage</h2>
<p class="First">Store lyophilized TNKase at controlled room temperature not to exceed 30°C (86°F) or under refrigeration 2–8°C (36–46°F). Do not use beyond the expiration date stamped on the vial. </p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="References"></a><a name="section-11"></a><p></p>
<h1>REFERENCES</h1>
<p class="First"></p>
<ol>
<li>ASSENT-2 Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>: the ASSENT-2 double-blind randomised trial. <span class="Italics">Lancet</span>1999;354:716-22.</li>
<li>Cannon CP, Gibson CM, McCabe CH, Adgey AAJ, Schweiger MJ, Sequeira RF, et al. TNK-tissue <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> activator compared with front-loaded alteplase in <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>. Results of the TIMI 10B trial. <span class="Italics">Circulation</span>1998;98:2805–14.</li>
<li>Van de Werf F, Cannon CP, Luyten A, Houbracken K, McCabe CH, Berioli S, et al. Safety assessment of a single bolus administration of TNK tissue- <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> activator in <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>: the ASSENT-1 trial. <span class="Italics">Am Heart J</span>1999;137:786–91.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1></h1>
<table width="100%">
<col width="40%">
<col width="60%">
<tbody class="Headless">
<tr class="First"><td colspan="2">
<span class="Bold">TNKase<span class="Sup">®</span> [Tenecteplase]</span><br><br>
</td></tr>
<tr class="Last">
<td>Manufactured by:<br><br><span class="Bold">Genentech, Inc.</span><br>A Member of the Roche Group<br>1 DNA Way<br>South San Francisco, CA 94080-4990</td>
<td align="right">4851700<br>Initial US Approval June 2000<br>Revision Date May 2011<br><br>TNKase is a registered Trademark of Genentech, Inc.<br><span class="Sup">©</span>2011 Genentech, Inc.</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel"></a><a name="section-13"></a><p></p>
<div class="Figure">
<img alt="TNKase 50mg Principal Display Panel" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66a1e273-ab59-4e7a-a223-a96b86501f51&amp;name=1a9e312c-f0b0-4139-b526-b904b80883a4-03.jpg"><p class="MultiMediaCaption">TNKase 50mg
                        Principal Display Panel</p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TNKASE 		
					</strong><br><span class="contentTableReg">tenecteplase kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50242-120</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50242-120-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, SINGLE-USE </td>
<td class="formItem">50 mg</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL, SINGLE-USE </td>
<td class="formItem">10 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>TNKASE 		
					</strong><br><span class="contentTableReg">tenecteplase injection, solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Tenecteplase</strong> (tenecteplase) </td>
<td class="formItem">Tenecteplase</td>
<td class="formItem">52.5 mg  in 50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Arginine</strong></td>
<td class="formItem">0.55 g  in 50 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Phosphoric Acid</strong></td>
<td class="formItem">0.17 g  in 50 mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Polysorbate 20</strong></td>
<td class="formItem">4.3 mg  in 50 mg</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">50 mg in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103909</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>STERILE WATER 		
					</strong><br><span class="contentTableReg">water injection</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103909</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103909</td>
<td class="formItem">06/02/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Genentech, Inc.
							(080129000)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Genentech, Inc. (080129000)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Genentech, Inc. (SSF)</td>
<td class="formItem"></td>
<td class="formItem">080129000</td>
<td class="formItem">MANUFACTURE, API MANUFACTURE, ANALYSIS</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1a9e312c-f0b0-4139-b526-b904b80883a4</div>
<div>Set id: 66a1e273-ab59-4e7a-a223-a96b86501f51</div>
<div>Version: 1</div>
<div>Effective Time: 20110817</div>
</div>
</div> <div class="DistributorName">Genentech, Inc.</div></p>
</body></html>
